Meet Ravi, Nafla, Cold Bay and Xydo at the 2022 GROOVL1N US Tour + Ticket Giveaway

Ciera Reeves
0


RAVI and his labelmates are embarking on their first US tour this March for the 2022 GROOVL1N US Tour


All four artists under the label including NaflaCold Bay and Xydo, will be joining CEO RAVI as they stop by Los Angeles, Dallas, Atlanta, Chicago, and New York!


RAVI created his own label back in 2019 and combined the words “GROOVE” and “GOBLIN” to come up with GROOVL1N. While running GROOVL1N he also created a second label called The L1VE while continuing to be a member of K-Pop Group VIXX. RAVI works continuously every day for himself and his artists while also becoming one of the most copyrighted K-Pop idols in the industry with all the music he creates. He’ll be releasing his 2nd LP LOVE&FIGHT consisting of 11 tracks to release on February 8, 6PM KST with the title track ‘VIRUS’ which is out now.



Nafla is most known for being on the popular Korean Hip Hop show Show Me the Money 777 where he was crowned the winner and took home 1st place. He was the latest to join GROOVL1N back in 2020. His enthralling rap skills amps up the crowd with his songs ‘mobb tang’ and ‘run!’



Cold Bay and Xydo are both R&B artists. Cold Bay’s ‘Love is Poison’ is his latest release under GROOVL1N and really highlights his captivating vocals. 



Xydo’s song ‘Betting’ with pH-1 is the perfect mix of pop and R&B rhythm. His most recent hit ‘Paradigm’ is quite the opposite being a more smooth and relaxed hit.



VVIP Tickets are on sale at kpoptickets.com and fans will have a Fansign, Hi-Touch, Group Photo & more with GROOVL1N for only $199!


It's your chance to win a free GROOVL1N Tour T5 ticket. To enter join the raffle. The more points you earn the higher your chance of being selected. You can follow us on Twitter, Instagram, our Newsletter or comment on this post to earn points. 


Enter the Giveaway!




Check out GROOVL1N’s Links below:

GROOVL1N Youtube Channel

Instagram | Facebook Twitter



Source: Studio Pav 

Post a Comment

0Comments

Post a Comment (0)
To Top